At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages.
By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the body’s native immune response against cancer.
Company Details
- Employees
- 10
- Founded
- 2022
- Address
- Zurich, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Biotech, Therapeutics, Immuno-oncology.
- HQ
- Zurich
Adularia Questions
Adularia's LinkedIn profile is https://ch.linkedin.com/company/adularia-therapeutics
Adularia has
10 employees.
View email and phone details for 10
employees at Adularia.
Adularia's industry is
Biotechnology Research
Adularia's top competitors are
Glycoera Ag,
Synendos Therapeutics Ag,
Muvon Therapeutics Ag,
Araris Biotech Ag,
Navignostics Ag,
Fimmcyte,
Nagi Bioscience,
Haya Therapeutics,
Inkvivo Technologies Ag,
Tandem Therapeutics.
Adularia's categories are Biotechnology Research
Adularia's founding year is 2022
